Pure Global
NCT06413316

ABC-CT Pre-School Feasibility Study

Autism Biomarkers Consortium for Clinical Trials (ABC-CT) Pre-School Feasibility Study
Yale University·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Autism Spectrum Disorder
Study type
Observational
Sponsor & location
Primary sponsor
Yale University
Location
Los Angeles,New Haven,Boston,Durham,Seattle, United States of America
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2024
End date
Jun 30, 2025
Enrollment
50 participants
Primary outcome

N170 Latency to Upright Human Faces,N170 Latency to Upright Human Faces,Oculomotor Index of Gaze to Human Faces (OMI),Oculomotor Index of Gaze to Human Faces (OMI)

Summary

This is a multicenter study that aims to determine whether the EEG and ET experiments studied
 in the ABC-CT Phase 1 and ABC-CT Confirmation studies can be successfully used with
 3-5-year-old children and to determine the viability of these measures as potential
 biomarkers in 3-5-year-old children with ASD. Blood (DNA) samples will be collected from
 participants with ASD and biological parents for future genomic analyses, and raw, processed,
 and analyzed data will be shared to create a community resource accessible for use by all
 qualified investigators. These objectives are designed to advance the long term objective of
 developing promising biomarkers via the FDA Biomarker Qualification Program. This feasibility
 study aims to enroll 25 ASD and 25 TD eligible participants who are 3-5 years old.

ICD-10 classifications
Childhood autismAtypical autismAsperger syndromeNeurotic disorder, unspecifiedMental and behavioural disorders
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06413316
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06413316 through Pure Global AI's free database. This phase not specified trial is sponsored by Yale University and is currently Not yet recruiting. The study focuses on Autism Spectrum Disorder. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.